D.A. Davidson & CO. Has $58.45 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

D.A. Davidson & CO. raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,241 shares of the medical research company's stock after acquiring an additional 6,507 shares during the quarter. D.A. Davidson & CO.'s holdings in Amgen were worth $58,446,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AMGN. State Street Corp increased its holdings in shares of Amgen by 1.2% during the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company's stock valued at $9,446,236,000 after acquiring an additional 345,537 shares during the last quarter. Geode Capital Management LLC boosted its position in Amgen by 0.9% during the third quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company's stock worth $3,893,771,000 after purchasing an additional 103,851 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Amgen by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company's stock valued at $3,393,718,000 after purchasing an additional 251,876 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Amgen by 11.7% in the third quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock valued at $1,657,183,000 after purchasing an additional 538,545 shares during the period. Finally, Pathway Financial Advisers LLC lifted its stake in shares of Amgen by 33,125.4% in the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after buying an additional 4,446,757 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This trade represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last three months. Company insiders own 0.69% of the company's stock.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $5.08 during midday trading on Friday, reaching $303.01. 3,260,757 shares of the company's stock were exchanged, compared to its average volume of 3,124,757. The firm has a market capitalization of $162.78 billion, a PE ratio of 40.13, a price-to-earnings-growth ratio of 2.55 and a beta of 0.56. The company's 50 day simple moving average is $276.27 and its two-hundred day simple moving average is $300.59. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts expect that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.14%. Amgen's payout ratio is currently 126.09%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. William Blair reiterated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Citigroup lowered their price target on Amgen from $310.00 to $295.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Jefferies Financial Group reiterated a "buy" rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Wells Fargo & Company decreased their target price on Amgen from $335.00 to $280.00 and set an "equal weight" rating for the company in a research note on Friday, January 10th. Finally, Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and a consensus target price of $314.09.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.